Dermatitis News

Delgocitinib cream has shown efficacy in the treatment of hand eczema in two phase 3 trials.

Cendakimab was effective and generally safe in the treatment of moderate to severe atopic dermatitis in adults, according to a press release.

Healio has compiled July’s most-read news in dermatology.

A new imaging device effectively monitored skin texture changes in patients with skin of color with atopic dermatitis and xerosis following a prebiotic skincare regimen, according to a study.

New results evaluating the efficacy and safety of nemolizumab for the treatment of adult and adolescent patients with moderate to severe atopic dermatitis were published in The Lancet, Galderma announced in a press release.

The American Skin Association has announced the recipients of its 2024 research grants for skin cancer and diseases, according to a press release.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Anzupgo for the treatment of chronic hand eczema in adults, LEO Pharma announced in a press release.

Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

While the art of tattooing has been present for centuries, the medical implications are only recently coming to light with modern medicine.

Instead of patch testing with all allergens in any given group, using an optimized subset of allergens to test for allergic contact dermatitis can provide a similar level of care at a reduced cost, according to a study.